Applied UV Announces the Appointment of James Alecxih as Chief Executive Officer

December 9, 2021 8:00 AM

Highly Accomplished Executive with Proven Track Record of Leading Healthcare BusinessesQ Saeed to transition to consultant to the CompanyMOUNT VERNON, NY / ACCESSWIRE / December 9, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an industry leader in air and surface pathogen elimination technology today announced that its Board of Directors has appointed James Alecxih as Chief Executive Officer and as a member of the...

Read more

Oncology Pharma Year End Review and Outlook

December 9, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provide an outlook for what to look for in the coming months and year ahead. The Company is proud of the progress it has made this past year including the addition of a renowned Chairman to the Scientific Advisory Board, retaining a PCAOB audit firm,...

Read more

Wuhan Acquires Remaining Shares in Tsime

December 8, 2021 8:00 AM

CAPE TOWN, SA / ACCESSWIRE / December 8, 2021 / WUHAN GENERAL GROUP (CHINA), INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:Following the acquisition of 60% of Tsime Pharmaceuticals and Medical Supplies (Pty) Ltd ("Tsime") in 2020, WGG has now reached an agreement with the remaining...

Read more

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

December 8, 2021 7:30 AM

Results suggest broader applications for DehydraTECH-CBD beyond hypertensionKELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECHTM-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its...

Read more

BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors

December 8, 2021 2:20 AM

LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV)BioInvent's pipeline expanding to four drug candidates in five clinical trialsLund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a...

Read more

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco

December 7, 2021 5:50 PM

TUCSON, AZ / ACCESSWIRE / December 7, 2021 / Aqualung Therapeutics Corp., an early stage immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, will be presenting at the annual Biotech Showcase in San Francisco in conjunction with the JP Morgan Healthcare conference, January 11th at 10:30am pacific time, Hilton Hotel, Franciscan C Ballroom.As one of the biggest annual...

Read more

Medspresso Coffee Webinar Now Available for Viewing

December 7, 2021 8:25 AM

CAPE TOWN, SA / ACCESSWIRE / December 7, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:Medspresso™ is delighted to share the recorded version of the coffee webinar The Art, Craft, and Science of Coffee held December 01, 2021 is now available for viewing and can...

Read more

CB Scientific, Inc. Executes Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd.

December 7, 2021 6:00 AM

Partnership to provide high volume manufacturing capability and facilitate obtaining requisite government approvalsESCONDIDO, CA / ACCESSWIRE / December 7, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced Shenzhen Pump Medical System Co., Ltd. (SPMS), a leading Chinese developer, manufacturer, and distributor of medical equipment and devices focusing on cardiovascular diagnostic systems, has issued a formal Letter...

Read more

Marvel Biosciences to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

December 3, 2021 8:00 AM

CALGARY, AB / ACCESSWIRE / December 3, 2021 / Marvel Biosciences (TSXV:MRVL), and its wholly owned subsidiary, Marvel Biotechnology Inc., today announced that it will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8th at 2:00 PM EST. President and CSO Mark Williams will be hosting the presentation and answering questions from investors.To access the live presentation, please use the following information:SNN...

Read more

Oxford Nanopore Technologies plc Announces Technology Updates

December 2, 2021 2:00 AM

OXFORD, UK / ACCESSWIRE / December 2, 2021 // Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencerOxford, UK: Oxford Nanopore has provided a technology update at its Nanopore Community Meeting,...

Read more

Applied UV Continues Global Expansion with Airocide(R) Installations in Thailand at the Acclaimed Armed Forces Research Institute of Medical Sciences ("AFRIMS")

December 1, 2021 8:30 AM

AFRIMS to install Airocide® technology to protect visitors and staffAFRIMS is a biomedical research facility of the U.S. Army's Walter Reed Army Institute of ResearchMOUNT VERNON, NY / ACCESSWIRE / December 1, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology...

Read more

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

December 1, 2021 7:58 AM

TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis.The...

Read more

Q2 Interim Report - Promising Results Published at ESMO

December 1, 2021 1:45 AM

UPPSALA, SE / ACCESSWIRE / December 1, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)SEK 000sQ221/22Q220/21May-Oct 21/22May-Oct 20/21Full year20/21Net sales268446493842,077Operating profit (loss)-14,314-8,285-26,552-16,950-40,181Profit (loss) for the period-14,388-8,208-26,613-16,581-39,482Earnings per share after dilution-0.51-0.29-0.93-0.59-1.39Significant events during the second quarterBiovica has strengthened its...

Read more

Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update

November 30, 2021 8:00 PM

RICHMOND HILL, ON / ACCESSWIRE / November 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management...

Read more

Clairvoyant Therapeutics Raises More Than $3 Million in Seed Financing, Adds Bench Strength to Senior Leadership Team

November 30, 2021 8:00 AM

Institutional investor support to fund next stage investigation of psilocybin therapy as treatment for alcohol use disorderRenowned addiction specialist Mark Tyndall MD ScD joins Clairvoyant as Chief Medical OfficerVANCOUVER, BC / ACCESSWIRE / November 30, 2021 / Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the Company has...

Read more

CB Scientific, Inc. Announces Intent to Convene a Special Meeting of the Stockholders

November 30, 2021 7:50 AM

Agenda to include matters necessary to better position the company for anticipated growth and developmentESCONDIDO, CA / ACCESSWIRE / November 30, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") has announced it will convene a Special Stockholder Meeting in order to gain approval to implement a number of significant enhancements which management believes will better position CBSC to attain its stated business objectives. As...

Read more

Oncology Pharma Research and Vision

November 30, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics. The Company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the fields of oncology and therapeutics with leadership to...

Read more

American CryoStem Completes Clinical Protocol Design for Long COVID Study

November 30, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 30, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies today announced completion of its Phase I clinical protocol design for the treatment of Long COVID. American CryoStem anticipates that the protocol will be filed as an FDA Phase I IND in cooperation with a major US medical center in Q-1, 2022.Medical complications...

Read more

Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022

November 25, 2021 2:50 AM

LUND, SWEDEN / ACCESSWIRE / November 25, 2021 / BioInvent International (STO:BINV)Lund, Sweden - November 25, 2021 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent") Annual General Meeting in 2022 have now been appointed.The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2022:Laura Feinleib,...

Read more

Hemogenyx Pharmaceuticals PLC Announces Convertible Loans Repayment

November 24, 2021 9:55 AM

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Convertible Loans RepaymentLONDON, UK / ACCESSWIRE / November 24, 2021 / As originally announced in October 2018, Hemogenyx-Cell S.A. ("Hemogenyx-Cell") and Immugenyx LLC ("Immugenyx"), each wholly-owned subsidiaries of Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, each entered into...

Read more